[{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIAID-sponsored Trial of M-001 Validates Previous Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital Corp","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"BiondVax Announces Successful Closing of $9.8 million Follow-on Underwritten Offering of ADSs Including Exercise of the Over-Allotment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Society","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BiondVax Signs Definitive Collaboration Agreement for The Development of A Pipeline of Innovative Nanosized Antibody (NanoAb) Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Innovation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax Receives Supportive Scientific Advice from The Paul Ehrlich Institute (PEI) for COVID-19 NanoAb Development Plans Including First-In-Human Phase 1\/2a safety and efficacy clinical trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Institute for Multidisciplinary Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BiondVax\u2019s Strategic Research Collaboration: Significant Progress Towards Development Of Innovative Nanosized Antibodies (NanoAbs) for Therapeutic Indications in Addition to COVID-19","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax to Present at Recent Advances in Fermentation Technology (RAFT) 14 Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax Reports Successful Results In Preclinical In Vivo Study Of Its Innovative Inhaled COVID-19 NanoAb Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"BiondVax Announces Pricing of $8 Million Underwritten Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"BiondVax Announces Closing of $8 Million Underwritten Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax's Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax\u2019s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Scinai Immunotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biondvax Signs Exclusive License Agreement for Development and Commercialization of a Novel Anti-IL-17 Antibody for Treatment of Autoimmune and Inflammatory Diseases Including Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scinai Announces Promising Results in a Psoriatic Human Skin Model","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by BiondVax Pharmaceuticals
The company intends to use the net proceeds for research and development of its pipeline of Alpaca-derived nanosized antibodies (NanoAbs) targeting SARS-CoV-2 variants.
The company intends to use the net proceeds for research and development of its pipeline of Alpaca-derived nanosized antibodies (NanoAbs) targeting SARS-CoV-2 variants.
Scinai Immunotherapeutics is developing a IL-17A Inhibitor antibody drug candidate, which is currently being evaluated for the treatment of patients with mild to moderate plaque psoriasis.
The Company will use the proceeds for research and development of its pipeline, including NanoAb-based inflammation and immunology biological therapeutics for autoimmune and infectious diseases such as psoriasis, psoriatic arthritis, asthma, wet AMD and COVID-19.
The Company will use the proceeds for research and development of its pipeline, including NanoAb-based inflammation and immunology biological therapeutics for autoimmune and infectious diseases such as psoriasis, psoriatic arthritis, asthma, wet AMD and COVID-19.
NanoAbs (alpaca-derived nanosized antibody) also known as VHH-antibodies, exhibit potential as biobetter therapies for a wide range of diseases. Scinai is developing NanoAbs addressing diseases with large unmet medical needs and attractive commercial opportunities, such as psoriasis.
Lead Product(s):
Alpaca-derived Nanosized Antibody
The agreement aims to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) as treatments for all potential indications, starting with psoriasis and psoriatic arthritis.
NanoAbs (alpaca-derived nanosized antibodies), exhibit potential for superior therapies for a wide range of diseases. NanoAb is currently studied for the treatment of COVID-19, exhibits significant competitive advantages over existing mAbs and oral therapies.
Lead Product(s):
Alpaca-derived Nanosized Antibody
NanoAbs ia an alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies*, exhibit potential for superior therapies for a wide range of diseases. Product is being developed for treatment of COVID-19.
Alpaca-derived nanosized antibodies, also known as VHH-antibodies, exhibit potential for superior therapies for a wide range of diseases. NanoAb, for treatment of COVID-19, exhibits significant competitive advantages over existing mAbs and oral therapies.
Lead Product(s):
Alpaca-derived Nanosized Antibody
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
